Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 30, 2021 - Issue 7
Submit an article Journal homepage
14,945
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

Fezolinetant in the treatment of vasomotor symptoms associated with menopause

Herman Depyperea Breast and Menopause Clinic, University Hospital, Ghent, BelgiumCorrespondence[email protected]
View further author information
,
Christopher Lademacherb Global Development, Astellas Pharma Global Development, Northbrook, IL, USAView further author information
,
Emad Siddiquic Medical Affairs, Astellas Pharma Medical and Development, Chertsey, UKView further author information
&
Graeme L Fraserd Former Chief Scientific Officer of Ogeda SA, Gosselies, Belgium and Consultant for Astellas Pharma Inc.View further author information
Pages 681-694 | Received 28 Sep 2020, Accepted 17 Feb 2021, Published online: 12 Jul 2021

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Paru S David, Taryn L Smith, Hannah C Nordhues & Juliana M Kling. (2022) A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms. International Journal of Women's Health 14, pages 353-361.
Read now

Articles from other publishers (6)

Kimball A Johnson, Nancy Martin, Rossella E Nappi, Genevieve Neal-Perry, Marla Shapiro, Petra Stute, Rebecca C Thurston, Wendy Wolfman, Marci English, Catherine Franklin, Misun Lee & Nanette Santoro. (2023) Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of Clinical Endocrinology & Metabolism 108:8, pages 1981-1997.
Crossref
Genevieve Neal-Perry, Antonio Cano, Samuel Lederman, Rossella E. Nappi, Nanette Santoro, Wendy Wolfman, Marci English, Catherine Franklin, Udaya Valluri & Faith D. Ottery. (2023) Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause. Obstetrics & Gynecology 141:4, pages 737-747.
Crossref
Samuel Lederman, Faith D Ottery, Antonio Cano, Nanette Santoro, Marla Shapiro, Petra Stute, Rebecca C Thurston, Marci English, Catherine Franklin, Misun Lee & Genevieve Neal-Perry. (2023) Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. The Lancet 401:10382, pages 1091-1102.
Crossref
Meijun Pan, Jing Zhou, Xinyao Pan, Jing Wang, Qing Qi & Ling Wang. (2023) Drugs for the treatment of postmenopausal symptoms: Hormonal and non-hormonal therapy. Life Sciences 312, pages 121255.
Crossref
Melissa Conklin, Dana Siegel, Elizabeth S. Ginsburg & Cassandra Roeca. 2020. Handbook of Gynecology. Handbook of Gynecology 1 13 .
C.M. Schooling. (2022) Genetic validation of neurokinin 3 receptor antagonists for ischemic heart disease prevention in men – A one-sample Mendelian randomization study. eBioMedicine 77, pages 103901.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.